Samsung Electronics Co., Ltd.

Samsung Life Welfare Foundation

Saet Byoul Lee

Kyung Ah Kim

Ji Min Lee

Yun Ju Jeong

Jae Young Choi

Kwang Ho Cheong

Bo Gyou Kim

Young Mi Oh

Seung Hyun Lee

Powei Lin

Jae Woong Hwang

Yun Jeong Song

Seunghyun Lee

Youngwook Kim

Geun Tak Kim

Mi Young Cho

Hyo Seon Lee

Seung Ja Oh

Jae Hyun Choi

Kyung-ah Kim

Ho Yeong Song

Keunchil Park

Seungja Oh

Geun Woong Kim

Soo-yeon Jung

Jimin Lee

Hye Won Park

Yumi Lee

Young Kue Han

Yoon Aa Choi

Yunju Jeong

A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

Biomarker Hsp90 for predicting effect of a c-Met inhibitor

A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, 'c-Met/EGFR dual inhibitor') and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.

Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor

Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.

Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases

A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Method of combination therapy using an anti-C-Met antibody

A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.

Method of combination therapy using an EGFR antagonist and anti-c-Met antibody

An anti-EGFR/anti-HER2 bispecific antibody including an anti-EGFR DARPin and an anti-HER2 antibody, a pharmaceutical composition including the bispecific antibody, a method of preparing the bispecific antibody, and a method of reducing a side effect and/or enhancing efficacy of an anti-HER2 antibody using an anti-EGFR DARPin.

Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins

A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.

Use of Cbl as biomarker for identifying subject suitable for treatment with anti-c-Met antibody

An anti c-Met antibody, a composition comprising the antibody, and a method for preventing or treating cancer by administering the composition is provided.

Anti c-Met humanized antibody and uses thereof

Growing community of inventors

Seoul, South Korea

Saet Byoul Lee